search
Back to results

Sphenopalatine Ganglion Stimulation for the Acute Treatment of Cluster Headache

Primary Purpose

Chronic Cluster Headache

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Stimulation (Sub-perception)
Stimulation (Full)
Control
Sponsored by
Autonomic Technologies, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Cluster Headache focused on measuring Chronic Cluster Headache

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age from 18 to 65 years old (inclusive).
  • Subject has been diagnosed with chronic cluster headache according to the 2004 International Headache Society (IHS) criteria 3.1.2.
  • Subject reports a minimum of 4 cluster headaches per week.
  • Subject reports dissatisfaction with current cluster headache treatment (Criterion includes both preventive or abortive therapy per the Investigator's standard of care. Reasons for dissatisfaction with existing headache therapies may include failure of therapies, contraindication, side effects of therapies, or patient refusal of available therapies)
  • Subject is able to distinguish cluster headaches from other headaches (i.e., tension-type headaches).
  • Subject has the ability to read and comprehend, and to reliably record information as required by the Protocol.
  • Subject is able to provide written informed consent prior to participation in the study.

Exclusion Criteria:

  • Subject has had a change in type or dosage of prophylactic headache medications < one (1) month prior to study enrollment
  • Subject has undergone facial surgery in the area of the pterygopalatine fossa or zygomaticomaxillary buttress ipsilateral to the planned implant site within the last four (4) months.
  • Subject has active oral or dental abscess.
  • Subject has been treated with radiation to the facial region within the last six (6) months.
  • Subject has been diagnosed with any major infectious processes such as osteomyelitis, or primary or secondary malignancies involving the face that have been active or required treatment in the past six (6) months.
  • Subject has other significant pain problem that might confound the study assessments in the opinion of the Investigator.
  • Subject is a woman of childbearing age who is pregnant, nursing, or not using contraception.
  • Subject is currently participating or has participated in the last month in another clinical study in which the subject has, is, or will be exposed to an investigational or non-investigational drug or device.
  • Subject is felt to be at risk of non-compliance (e.g., for completing the diary or maintaining a stable headache medicine regimen) in the Investigator's opinion.
  • Subject has had previous lesional radio-frequency ablation of the ipsilateral sphenopalatine ganglion (SPG).
  • Subject has had blocks of the ipsilateral SPG in the last three (3) months.
  • Subject has undergone botulinum toxin injections of the head and/or neck in the last three (3) months.
  • Subject has or requires a pacemaker/defibrillator or other implantable device having a sense amplifier.
  • Subject has a history of bleeding disorders or coagulopathy or is unable to discontinue anticoagulation, antiplatelet, or GP IIb IIIa inhibitor medication in preparation for the implantation procedure.
  • Subject is not suitable for the study for any reason in the judgment of the Investigator.

Sites / Locations

  • Citadelle Hospital
  • Danish Headache Center, Dept. of Neurology, Glostrup Hospital
  • Headache Center, Dept. of Neurology, University Duisburg-Essen
  • Institut fur systemische Neurowissenschaften, Universitastsklinikum Hamburg-Eppendorf (UKE)
  • Department of Neurology, University Clinic Hospital, University of Valencia

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Placebo Comparator

Experimental

Experimental

Arm Label

Placebo

Sub-perception

Full Stimulation

Arm Description

Outcomes

Primary Outcome Measures

Number of device related Serious Adverse Events (SAEs)
Acute Pain Relief response (as defined by patient)

Secondary Outcome Measures

Pain Freedom
Rescue medication use
Use of medications to treat headache pain within 90 minutes after initiating therapy.
Pain Relief after initiating therapy
Pain Relief after initiating therapy
Pain Relief after initiating therapy

Full Information

First Posted
December 3, 2010
Last Updated
December 28, 2015
Sponsor
Autonomic Technologies, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01255813
Brief Title
Sphenopalatine Ganglion Stimulation for the Acute Treatment of Cluster Headache
Official Title
Sphenopalatine Ganglion Stimulation for the Acute Treatment of Cluster Headache
Study Type
Interventional

2. Study Status

Record Verification Date
December 2015
Overall Recruitment Status
Completed
Study Start Date
December 2010 (undefined)
Primary Completion Date
March 2013 (Actual)
Study Completion Date
March 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Autonomic Technologies, Inc.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of the proposed clinical study is to evaluate the use of an implanted Neurostimulator to provide Sphenopalatine Ganglion (SPG) stimulation for the management of the pain associated with cluster headaches.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Cluster Headache
Keywords
Chronic Cluster Headache

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
43 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Title
Sub-perception
Arm Type
Experimental
Arm Title
Full Stimulation
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
Stimulation (Sub-perception)
Intervention Description
Stimulation applied below the perception threshold
Intervention Type
Device
Intervention Name(s)
Stimulation (Full)
Intervention Description
Stimulation applied above the perception threshold
Intervention Type
Other
Intervention Name(s)
Control
Intervention Description
No stimulation applied
Primary Outcome Measure Information:
Title
Number of device related Serious Adverse Events (SAEs)
Time Frame
Implant through the Experimental Period
Title
Acute Pain Relief response (as defined by patient)
Time Frame
15 minutes
Secondary Outcome Measure Information:
Title
Pain Freedom
Time Frame
15 minutes
Title
Rescue medication use
Description
Use of medications to treat headache pain within 90 minutes after initiating therapy.
Time Frame
90 minutes
Title
Pain Relief after initiating therapy
Time Frame
30 minutes
Title
Pain Relief after initiating therapy
Time Frame
60 minutes
Title
Pain Relief after initiating therapy
Time Frame
90 minutes

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age from 18 to 65 years old (inclusive). Subject has been diagnosed with chronic cluster headache according to the 2004 International Headache Society (IHS) criteria 3.1.2. Subject reports a minimum of 4 cluster headaches per week. Subject reports dissatisfaction with current cluster headache treatment (Criterion includes both preventive or abortive therapy per the Investigator's standard of care. Reasons for dissatisfaction with existing headache therapies may include failure of therapies, contraindication, side effects of therapies, or patient refusal of available therapies) Subject is able to distinguish cluster headaches from other headaches (i.e., tension-type headaches). Subject has the ability to read and comprehend, and to reliably record information as required by the Protocol. Subject is able to provide written informed consent prior to participation in the study. Exclusion Criteria: Subject has had a change in type or dosage of prophylactic headache medications < one (1) month prior to study enrollment Subject has undergone facial surgery in the area of the pterygopalatine fossa or zygomaticomaxillary buttress ipsilateral to the planned implant site within the last four (4) months. Subject has active oral or dental abscess. Subject has been treated with radiation to the facial region within the last six (6) months. Subject has been diagnosed with any major infectious processes such as osteomyelitis, or primary or secondary malignancies involving the face that have been active or required treatment in the past six (6) months. Subject has other significant pain problem that might confound the study assessments in the opinion of the Investigator. Subject is a woman of childbearing age who is pregnant, nursing, or not using contraception. Subject is currently participating or has participated in the last month in another clinical study in which the subject has, is, or will be exposed to an investigational or non-investigational drug or device. Subject is felt to be at risk of non-compliance (e.g., for completing the diary or maintaining a stable headache medicine regimen) in the Investigator's opinion. Subject has had previous lesional radio-frequency ablation of the ipsilateral sphenopalatine ganglion (SPG). Subject has had blocks of the ipsilateral SPG in the last three (3) months. Subject has undergone botulinum toxin injections of the head and/or neck in the last three (3) months. Subject has or requires a pacemaker/defibrillator or other implantable device having a sense amplifier. Subject has a history of bleeding disorders or coagulopathy or is unable to discontinue anticoagulation, antiplatelet, or GP IIb IIIa inhibitor medication in preparation for the implantation procedure. Subject is not suitable for the study for any reason in the judgment of the Investigator.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jean Schoenen, M.D.
Organizational Affiliation
Professor of Functional Neuroanatomy, Leige University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Citadelle Hospital
City
Liege
Country
Belgium
Facility Name
Danish Headache Center, Dept. of Neurology, Glostrup Hospital
City
Glostrup
ZIP/Postal Code
2600
Country
Denmark
Facility Name
Headache Center, Dept. of Neurology, University Duisburg-Essen
City
Essen
ZIP/Postal Code
45147
Country
Germany
Facility Name
Institut fur systemische Neurowissenschaften, Universitastsklinikum Hamburg-Eppendorf (UKE)
City
Hamburg
ZIP/Postal Code
20246
Country
Germany
Facility Name
Department of Neurology, University Clinic Hospital, University of Valencia
City
Valencia
ZIP/Postal Code
46010
Country
Spain

12. IPD Sharing Statement

Learn more about this trial

Sphenopalatine Ganglion Stimulation for the Acute Treatment of Cluster Headache

We'll reach out to this number within 24 hrs